[The effect of isoflurane anesthesia on dopamine release in rat striatum with pretreatment of imipramine]. 2006

Yushi Adachi, and Hideyuki Higuchi, and Kazuhiko Watanabe, and Tomiei Kazama, and Matsuyuki Doi, and Shigehito Sato
Intensive Care Unit, University Hospital, Hamamatsu University School of Medicine, Hamamatsu 431-3192.

BACKGROUND Isoflurane anesthesia has been shown to have a possibility of inducing a biphasic effect on dopamine release in rat striatum. The current study investigated the effect of isoflurane on the extracellular concentration of dopamine in the rat striatum pretreated by a classical antidepressant, imipramine, using in vivo microdialysis techniques. METHODS After intraperitoneal administration of 5 and 10 mg x kg(-10 of imipramine, the rats were anesthetized with 1 and 2.5% isoflurane inhalation. The control group was injected saline. Isoflurane anesthesia increased the extracellular concentration of dopamine metabolites without any change in dopamine concentration. RESULTS Under pretreatment of 5 mg x kg(-1) of imipramine, the effect of isoflurane on the change in dopamine and its metabolites was preserved. Whereas, 10 mg x kg(-1) of imipramine pretreatment induced a marked increase in the extracellular concentration of dopamine when only 1% isoflurane was applied but not with 2.5% isoflurane. In the rat administered 10 mg x kg(-1) of imipramine, anesthesia-induced increase of 3-methoxytyramine was not found. CONCLUSIONS Our previous investigation suggested that the isoflurane anesthesia has a biphasic effect on dopamine release in rat striatum under pargyline pretreatment. The same effect was shown in the rat administered imipramine. Isoflurane anesthesia might modify dopaminergic neural activity and release of neurotransmitters through different and complex ways.

UI MeSH Term Description Entries
D007099 Imipramine The prototypical tricyclic antidepressant. It has been used in major depression, dysthymia, bipolar depression, attention-deficit disorders, agoraphobia, and panic disorders. It has less sedative effect than some other members of this therapeutic group. Imidobenzyle,Imizin,4,4'-Methylenebis(3-hydroxy-2-naphthoic acid)-3-(10,11-dihydro-5H-dibenzo(b,f)azepin-5-yl)-N,N-dimethyl-1-propanamine (1:2),Imipramine Hydrochloride,Imipramine Monohydrochloride,Imipramine Pamoate,Janimine,Melipramine,Norchlorimipramine,Pryleugan,Tofranil
D007530 Isoflurane A stable, non-explosive inhalation anesthetic, relatively free from significant side effects.
D008297 Male Males
D003342 Corpus Striatum Striped GRAY MATTER and WHITE MATTER consisting of the NEOSTRIATUM and paleostriatum (GLOBUS PALLIDUS). It is located in front of and lateral to the THALAMUS in each cerebral hemisphere. The gray substance is made up of the CAUDATE NUCLEUS and the lentiform nucleus (the latter consisting of the GLOBUS PALLIDUS and PUTAMEN). The WHITE MATTER is the INTERNAL CAPSULE. Lenticular Nucleus,Lentiform Nucleus,Lentiform Nuclei,Nucleus Lentiformis,Lentiformis, Nucleus,Nuclei, Lentiform,Nucleus, Lenticular,Nucleus, Lentiform,Striatum, Corpus
D004298 Dopamine One of the catecholamine NEUROTRANSMITTERS in the brain. It is derived from TYROSINE and is the precursor to NOREPINEPHRINE and EPINEPHRINE. Dopamine is a major transmitter in the extrapyramidal system of the brain, and important in regulating movement. A family of receptors (RECEPTORS, DOPAMINE) mediate its action. Hydroxytyramine,3,4-Dihydroxyphenethylamine,4-(2-Aminoethyl)-1,2-benzenediol,Dopamine Hydrochloride,Intropin,3,4 Dihydroxyphenethylamine,Hydrochloride, Dopamine
D000769 Anesthesia, Inhalation Anesthesia caused by the breathing of anesthetic gases or vapors or by insufflating anesthetic gases or vapors into the respiratory tract. Insufflation Anesthesia,Anesthesia, Insufflation,Inhalation Anesthesia
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D000929 Antidepressive Agents, Tricyclic Substances that contain a fused three-ring moiety and are used in the treatment of depression. These drugs block the uptake of norepinephrine and serotonin into axon terminals and may block some subtypes of serotonin, adrenergic, and histamine receptors. However, the mechanism of their antidepressant effects is not clear because the therapeutic effects usually take weeks to develop and may reflect compensatory changes in the central nervous system. Antidepressants, Tricyclic,Tricyclic Antidepressant,Tricyclic Antidepressant Drug,Tricyclic Antidepressive Agent,Tricyclic Antidepressive Agents,Antidepressant Drugs, Tricyclic,Agent, Tricyclic Antidepressive,Agents, Tricyclic Antidepressive,Antidepressant Drug, Tricyclic,Antidepressant, Tricyclic,Antidepressive Agent, Tricyclic,Drug, Tricyclic Antidepressant,Drugs, Tricyclic Antidepressant,Tricyclic Antidepressant Drugs,Tricyclic Antidepressants
D017207 Rats, Sprague-Dawley A strain of albino rat used widely for experimental purposes because of its calmness and ease of handling. It was developed by the Sprague-Dawley Animal Company. Holtzman Rat,Rats, Holtzman,Sprague-Dawley Rat,Rats, Sprague Dawley,Holtzman Rats,Rat, Holtzman,Rat, Sprague-Dawley,Sprague Dawley Rat,Sprague Dawley Rats,Sprague-Dawley Rats
D051381 Rats The common name for the genus Rattus. Rattus,Rats, Laboratory,Rats, Norway,Rattus norvegicus,Laboratory Rat,Laboratory Rats,Norway Rat,Norway Rats,Rat,Rat, Laboratory,Rat, Norway,norvegicus, Rattus

Related Publications

Yushi Adachi, and Hideyuki Higuchi, and Kazuhiko Watanabe, and Tomiei Kazama, and Matsuyuki Doi, and Shigehito Sato
July 1981, Research communications in chemical pathology and pharmacology,
Yushi Adachi, and Hideyuki Higuchi, and Kazuhiko Watanabe, and Tomiei Kazama, and Matsuyuki Doi, and Shigehito Sato
November 1992, Journal of neurochemistry,
Yushi Adachi, and Hideyuki Higuchi, and Kazuhiko Watanabe, and Tomiei Kazama, and Matsuyuki Doi, and Shigehito Sato
January 1985, Regulatory peptides. Supplement,
Yushi Adachi, and Hideyuki Higuchi, and Kazuhiko Watanabe, and Tomiei Kazama, and Matsuyuki Doi, and Shigehito Sato
January 1986, Psychopharmacology,
Yushi Adachi, and Hideyuki Higuchi, and Kazuhiko Watanabe, and Tomiei Kazama, and Matsuyuki Doi, and Shigehito Sato
January 1975, European journal of pharmacology,
Yushi Adachi, and Hideyuki Higuchi, and Kazuhiko Watanabe, and Tomiei Kazama, and Matsuyuki Doi, and Shigehito Sato
May 2000, Synapse (New York, N.Y.),
Yushi Adachi, and Hideyuki Higuchi, and Kazuhiko Watanabe, and Tomiei Kazama, and Matsuyuki Doi, and Shigehito Sato
December 2012, Brain research bulletin,
Yushi Adachi, and Hideyuki Higuchi, and Kazuhiko Watanabe, and Tomiei Kazama, and Matsuyuki Doi, and Shigehito Sato
January 1982, Acta biologica et medica Germanica,
Yushi Adachi, and Hideyuki Higuchi, and Kazuhiko Watanabe, and Tomiei Kazama, and Matsuyuki Doi, and Shigehito Sato
January 1976, Biochemical pharmacology,
Yushi Adachi, and Hideyuki Higuchi, and Kazuhiko Watanabe, and Tomiei Kazama, and Matsuyuki Doi, and Shigehito Sato
January 1996, Brain research bulletin,
Copied contents to your clipboard!